A Enanta Pharmaceuticals recorrerá depois que um tribunal invalidar sua patente relacionada à Paxlovid da Pfizer. Enanta Pharmaceuticals will appeal after a court invalidated its patent related to Pfizer's Paxlovid.

A Enanta Pharmaceuticals planeja recorrer de uma decisão judicial de Massachusetts que ficou do lado da Pfizer, invalidando a patente da Enanta relacionada ao medicamento antiviral Covid-19 Paxlovid. Enanta Pharmaceuticals plans to appeal a Massachusetts court ruling that sided with Pfizer, invalidating Enanta's patent related to the COVID-19 antiviral drug Paxlovid. O processo da Enanta alegou violação de patente, mas o tribunal rejeitou suas reivindicações. Enanta's lawsuit claimed patent infringement, but the court dismissed their claims. Apesar do revés, o CEO da Enanta, Jay Luly, afirmou que a empresa continuará a defender suas patentes no Tribunal de Apelações para o Circuito Federal. Despite the setback, Enanta's CEO, Jay Luly, stated the company will continue to defend its patents in the Court of Appeals for the Federal Circuit.